A community assessment, open-label study of the safety, tolerability, and effectiveness of mixed amphetamine salts extended release in school-age children with ADHD
Authors:
- Paul J. AmbrosiniPAPaul J. Ambrosini
- on Behalf of the LADD.CAT Study GroupOGon Behalf of the LADD.CAT Study Group
- 9 December 2005
- journal article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 22 (2) , 427-440
Abstract
Objective: To assess the safety, tolerability, and effectiveness of mixed amphetamine salts extended release (MAS XR) in school-age children with attention-deficit/hyperactivity disorder (ADHD) treated in a community practice setting.Methods: Children aged 6–12 years (N = 2968) with DSM‐IV-defined ADHD entered a 9‐week prospective, open-label, non-comparative study of MAS XR at 386 sites. For at least 2 weeks before enrollment, subjects with well-controlled ADHD received their consistent dose of previously prescribed psychostimulant. Subsequently, this regimen was converted to an equivalent once-daily dose of 10-, 20-, or 30‐mg MAS XR, according to a conversion algorithm. Tolerability and safety were assessed based on reported treatment-emergent adverse events and observed changes in vital signs and body weight. Effectiveness was assessed using a parent-completed Conners’ Global Index Scale (CGIS‐P) measured 8 and 12 h postdose and a clinician-scored Clinical Global Impressions-Improvement (CGI‐I)...Keywords
This publication has 13 references indexed in Scilit:
- Analog Classroom Assessment of a Once-Daily Mixed Amphetamine Formulation, SLI381 (ADDERALL XR), in Children With ADHDJournal of the American Academy of Child & Adolescent Psychiatry, 2003
- A Feasibility Study of the Children's Medication Algorithm Project (CMAP) Algorithm for the Treatment of ADHDJournal of the American Academy of Child & Adolescent Psychiatry, 2003
- SLI381 (Adderall XR), a Two‐Component, Extended‐Release Formulation of Mixed Amphetamine Salts: Bioavailability of Three Test Formulations and Comparison of Fasted, Fed, and Sprinkled AdministrationPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2002
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of SLI381 (Adderall XR) in Children With Attention-Deficit/Hyperactivity DisorderPediatrics, 2002
- The epidemiology of attention‐deficit/hyperactivity disorder (ADHD): A public health viewMental Retardation and Developmental Disabilities Research Reviews, 2002
- Pediatric Psychotropic Medication Compliance: A Literature Review and Research-Based Suggestions for Improving Treatment ComplianceJournal of Child and Adolescent Psychopharmacology, 2001
- A Double-Blind, Placebo-Controlled Study of Adderall and Methylphenidate in the Treatment of Attention-Deficit/Hyperactivity DisorderJournal of the American Academy of Child & Adolescent Psychiatry, 2000
- A 14-Month Randomized Clinical Trial of Treatment Strategies for Attention-Deficit/Hyperactivity DisorderArchives of General Psychiatry, 1999
- Medication Treatment Strategies in the MTA Study: Relevance to Clinicians and ResearchersJournal of the American Academy of Child & Adolescent Psychiatry, 1996
- The Adolescent Outcome of Hyperactive Children Diagnosed by Research Criteria: I. An 8-Year Prospective Follow-up StudyJournal of the American Academy of Child & Adolescent Psychiatry, 1990